Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant NAPOX in Locally Advanced Esophagogastric Cancer
NCT04656041Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome injection in gastroesophageal junction adenocarcinoma, Esophagogastric Cancer, sponsored by Massachusetts General Hospital. Started Jun 2021; status: recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
gastroesophageal junction adenocarcinomaEsophagogastric Cancer
Beyond the preview
Go deeper on NCT04656041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656041.